Completed

N/A

16

NA

intrathecal rituximab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Lymphoma, Non-Hodgkin, Child, Only

12/20

08/22

Completed

N/A

 

Shanxi Academy of medical sciences Shanxi Dayi Hospital; Shanxi Dayi Hospital, This study was supported by Shanxi province the fund project of natural science (No.2015011089 )

breast cancer

 

 

Recruiting

N/A

60

 

Intravenous 100mg Rituximab, 1/week*4 ;Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (1000-1500mg/day)

The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital; The Chinese Peoples Liberation Army Hospital, The National High Technology Research andDevelopment Program (No. 2015AA020511)

Neuromyelitis Optica associated Optic Neuritis

 

 

Recruiting

N/A

50

RoW

Rituximab

The First Affiliated Hospital of Xiamen University

Nephrotic Syndrome, Rituximab, Children, Efficacy

03/26

03/28

Active, not recruiting

N/A

127

Europe

R-CHOP with doxorubicin, R-CHOP with doxorubicin analogue, R-COMP

Fondazione Italiana Linfomi - ETS

Lymphoma, Large B-Cell, Diffuse Large B-Cell

12/20

12/24

Not yet recruiting

N/A

102

 

Intravenous Rituximab and methotrexate plus Lenalidomide 25mg, qd, po, d1-10 ;Intravenous Rituximab and methotrexate

West China Hospital, Sichuan University; West China Hospital, Sichuan University, No

Primary central system B-cell lymphoma

 

 

Not yet recruiting

N/A

150

 

R-CHOP ;Support therapy

Beijing Hospital; Beijing Hospital, Beijing Committee of Science and Technology

diffuse large b-cell lymphoma

 

 

Completed

N/A

17478

RoW

interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab

IMPULS Endowment Fund

Multiple Sclerosis

12/21

12/21

Recruiting

N/A

100

 

rituximab 10mg ;rituximab 20mg ;rituximab 10mg ;rituximab 20mg

Department of Ophthalmology, Tangdu Hospital, Fourth Military Medical University; Tangdu Hospital, Fourth Military Medical University, self-raised

thyroid-associated orbitopathy and idiopathic orbital inflammatory syndrome

 

 

Recruiting

N/A

40

 

sintilimab combined with R-CHOP regimen

The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Wu Jieping Medical Foundation

diffuse large B-cell lymphoma

 

 

Recruiting

N/A

80

 

glucocorticoid and rituximablucocorticoid and rituximab ;glucocorticoid

The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine; The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, The three-year action plan to promote the development of clinical skills and clinical innovation in major clinical research projects (2020-2022)

Thyroid-Associated Ophthalmopathy

 

 

Active, not recruiting

N/A

45

Europe

Cladribine Oral Tablet, Mavenclade, Rituximab, Mabthera, Rixathon, Ocrelizumab, Ocrevus

Claudio Gobbi, Merck AG Switzerland

Multiple Sclerosis

10/22

10/22

Completed

N/A

1

RoW

Pfizer

Arthritis, Rheumatoid

12/22

12/22

Recruiting

N/A

1000

RoW

Intravenous steroid, Azathioprine, Mycophenolate Mofetil, Rituximab

Beijing Tiantan Hospital

NMO Spectrum Disorder, MRI, Multiple Sclerosis

12/22

12/25

Recruiting

N/A

30

 

Combination therapy

The 967th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ; The 967th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, self-financed

primary immune thrombocytopenia (ITP)

 

 

Not yet recruiting

N/A

14

 

Icaritin + R-CHOP

He'nan Cancer Hospital; He'nan Cancer Hospital, Beijing Shenogen Biomedical Co., Ltd.

Neutropenia due to chemotherapy (CIN)

 

 

Recruiting

N/A

36

Europe

Ibrutinib

IRCCS San Raffaele

PCNSL

01/23

08/23

Completed

N/A

235

 

None ;None

Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu 610041, China; West China School of Medicine and West China Hospital, Sichuan university, The research does not involve funding source

primary glomerular diseases

 

 

Recruiting

N/A

34

RoW

Rituximab, Gemcitabine, Dexamethasone, Cisplatin, PD-1 monoclonal antibody

Ou Bai, MD/PHD, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma

04/23

12/24

Recruiting

N/A

30

 

None; None; None

Dermatology Hospital of Southern Medical University; Dermatology Hospital of Southern Medical University, Self-raised

pemphigus

 

 

Recruiting

N/A

120

 

RCHOP ;R-miniCHOP ;R2 ;R2

Chinese Academy of Medical Science & Peking Union Medical College; Peking Union Medical College, Unit self financing

diffuse large B cell lymphoma

 

 

Not yet recruiting

N/A

30

NA

Rituximab, Mitoxantrone hydrochloride liposome, Cyclophosphamide, Vincristine/Vindesine, Prednisone

The First Affiliated Hospital with Nanjing Medical University

Diffuse Large B-cell Lymphoma

08/23

08/24

Recruiting

N/A

30

RoW

zanubrutinib 160 mg BID orally, rituximab: 375 mg/m2 intravenously on day 7, methotrexate: 3-3.5 g/m2 intravenously on day 1, temozolomide 100 mg on days 1-5

Huai'an First People's Hospital, Affiliated Hospital of Nantong University, The First People's Hospital of Changzhou, The Affiliated Hospital of Xuzhou Medical University, Northern Jiangsu People's Hospital

Primary Central Nervous System Lymphoma

04/26

04/26

Not yet recruiting

N/A

60

NA

Rituximab combined with tacrolimus induction + rituximab maintenance, Rituximab combined with tacrolimus induction + tacrolimus maintenance, Glucocorticoid combined with cyclophosphamide induction + maintenance

RenJi Hospital

Efficacy and Safety

09/23

09/24

Recruiting

N/A

2

RoW

prednisone,methylprednisone and cyclophosphamide, Rituximab

Beijing Friendship Hospital

Mild Cognitive Impairment, Idiopathic Membranous Nephropathy

09/25

09/25

Not yet recruiting

N/A

12

Europe

Measure of the circulating tumor DNA

Centre Henri Becquerel

Diffuse Large B Cell Lymphoma

11/24

05/25

Recruiting

N/A

1200

RoW

Corticosteroid, Steroid, Prednisone, Methylprednisone, Prednisolone, Hydroxychloroquine, Cyclophosphamide, Mycophenolate Mofetil, Azathioprine, Tacrolimus, Cyclosporine A, Rituximab, anti-CD20 antibody

Xiqiang Dang, The Children's Hospital Affiliated to Suzhou University, Shandong Provincial Hospital, Guizhou Provincial People's Hospital, LanZhou University, The First Affiliated Hospital of Inner Mongolia Medical College, People's Hospital of Zhangjiajie, Puyang Oilfield General Hospital, The First Affiliated Hospital of Anhui Medical University, Guizhou Maternal and Child Health Care Hospital, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Shenzhen Children's Hospital, The Second Affiliated Hospital of Harbin Medical University, Yichang Central People's Hospital, Xian Children's Hospital, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology, The First People's Hospital of Yunnan, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of Xinxiang Medical College, Shanxi Provincial Maternity and Children's Hospital, Liaocheng People's Hospital, Fujian Provincial Hospital, First Affiliated Hospital of Guangxi Medical University, Second Hospital of Lanzhou University, Guangzhou First People's Hospital, The Second Hospital of Shandong University, Children's Hospital of Hebei Province, Beijing Children's Hospital, Zhengzhou Children's Hospital, The Children's Hospital of Chongqing Medical University, Wuxi Children's Hospital, The Children's Hospital of Fudan University, Shanghai Children's Medical Center, Qilu Children's Hospital of Shandong University

Lupus Nephritis, Children, Steroid, Immunosuppressive Treatment

11/23

11/24

Recruiting

N/A

50

 

First line: Intravenous immunoglobulin and ocorticoid treatment; second line: depends on the Rankins score and by Rituximab or cyclic lindamides, or Mycophenolate or azathioprine

Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University, Chongqing Science and Techology Commission,and Children's Hospital of Chongqing Medical University

Autoimmune encephalitis

 

 

Recruiting

N/A

30

 

Selinexor+zanubrutinib+Rituximab

The Third People's Hospital of Fujian Province; The Third People's Hospital of Fujian Province, Antengene Corporation Limited

Diffuse Large B-cell Lymphoma

 

 

Recruiting

N/A

108

RoW

Rituximab, Involved Site Radiation Therapy

Zhongshan Ophthalmic Center, Sun Yat-sen University

Primary Ocular Adnexal MALT Lymphoma

12/27

12/27

Recruiting

N/A

20

RoW

Bortezomib, Velcade

Shahid Beheshti University of Medical Sciences

Antibody-mediated Rejection

05/24

10/25

Recruiting

N/A

36

RoW

Orelabrutinib in combination with rituximab

The First Affiliated Hospital of Xiamen University, The First Hospital of Jilin University, Fujian Cancer Hospital, Guangdong Provincial People's Hospital, Nanfang Hospital, Southern Medical University, The Second Affiliated Hospital of Dalian Medical University, Jiangxi Provincial Cancer Hospital, Wuhan Union Hospital, China, Shanxi Provincial Cancer Hospital, Chinese PLA General Hospital

Marginal Zone Lymphoma

06/27

06/27

Recruiting

N/A

70

Europe

blood samples

Hannover Medical School

Lung Transplantation, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies

07/24

12/24

Not yet recruiting

N/A

20

RoW

Mitoxantrone hydrochloride liposome injection, duoenda, RiTUXimab Injection, lituoxidankang, Cyclophosphamid, huanlinxianan, Vincristine, changchunxinjian, Prednisolone, ponisong

The First Hospital of Jilin University, CSPC Ouyi Pharmaceutical Co., Ltd.

Diffuse Large B-cell Lymphoma

08/24

08/26

Not yet recruiting

N/A

180

 

Nil ;Symptomatic treatment ;Hormone+Tacrolimus ;Hormone+Cyclophosphamide ;Hormone+Mycophenolate mofetil ester ;Rituximab

The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital; The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital, raise independently

Idiopathic membranous nephropathy

 

 

Not yet recruiting

N/A

98

 

Conventional therapy (steroid+rituximab) ;Conventional treatment + glutamine + clostridium butyric acid

Shanghai Children's Hospital; Shanghai Children's Hospital, Shanghai Science and Technology Committee

Primary nephrotic syndrome

 

 

Not yet recruiting

N/A

110

 

Cotrimoxazole treatment ;observation

Xijing Hospital; Xijing Hospital, National Natural Science Foundation of China (81770764)

glomerulonephritis

 

 

Recruiting

N/A

100

RoW

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Glomerulonephritis

12/24

12/25

Not yet recruiting

N/A

203

 

rituximab ;hormone combined with cyclophosphamide

Peking University Third Hospital; Peking University Third Hospital, Peking University third Hostipal

membranous nephropathy

 

 

Not yet recruiting

N/A

30

 

Obrutinib, lenalidomide and rituximab were given

Beijing Hospital; Beijing Hospital, National High Level Hospital Clinical Research funding

Diffuse large B-cell lymphoma

 

 

Recruiting

N/A

36

 

None; None

Shenzhen Second People’s Hospital; Shenzhen Second People’s Hospital, Shenzhen Key Medical Discipline Construction Fund (SZXK009) and Shenzhen medical and health three project(SZSM202211013).

Primary nephrotic syndrome

 

 

Not yet recruiting

N/A

92

 

Rituximab ;Conventional treatment

The Second People's Hospital of Shenzhen; The Second People's Hospital of Shenzhen, Clinical Research Fund of the Second People's Hospital of Shenzhen

minimal change disease (MCD)

 

 

Not yet recruiting

N/A

30

RoW

Selinexor combined with lenalidomide and rituximab

Ruijin Hospital

Lymphoma, Large B-Cell, Diffuse

06/25

06/25

Not yet recruiting

N/A

80

 

Bortezomib combined with rituximab; rituximab

Fujian Children's Hospital; Fujian Children's Hospital, self-funded

immune thrombocytopenia

 

 

Recruiting

N/A

39

 

zanubrutinib combined with rituximab

Beijing Hospital; Beijing Hospital, self funding

diffuse large B cell lymphoma

 

 

Not yet recruiting

N/A

135

 

Rituximab 400mg, once a week for 4 weeks ;100mg, once a week, for 4 consecutive weeks or 100mg + 500mg single treatment

Beijing Hospital; Beijing Hospital, Beijing Hospital Clinical Research 121 Project

myasthenia gravis

 

 

Not yet recruiting

N/A

12

 

Using Telitacicept

the First People's Hospital of qinzhou; the First People's Hospital of qinzhou, raise independently

Sjogren's syndrome combined with severe thrombocytopenia

 

 

Not yet recruiting

N/A

20

 

Complete 89Zr-rituximab immune PET before treating PTLD.

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, self-raised

posttransplant lymphoproliferative disorder

 

 

Not yet recruiting

N/A

40

 

rituximab; tacrolimus

The Seventh Affiliated Hospital Sun Yat-sen University; The?Seventh?Affiliated?Hospital?Sun?Yat-sen?University, The Seventh Affiliated Hospital, Sun Yat-sen University Clinical Research 735 Program

Idiopathic membranous nephropathy (IMN) is the most common pathological type of primary nephrotic syndrome in adults, characterised by subepithelial in situ immune complex deposition, complement activation, structural disorders of the podocyte, and functional impairment of the glomerular filtration barrier.